Back to Journals » OncoTargets and Therapy » Volume 11

Clinicopathological analysis of PD-L2 expression in colorectal cancer

Authors Guo PD, Sun ZW, Lai HJ, Yang J, Wu PP, Guo YD, Sun J

Received 15 June 2018

Accepted for publication 15 August 2018

Published 1 November 2018 Volume 2018:11 Pages 7635—7642

DOI https://doi.org/10.2147/OTT.S177329

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Peng-Da Guo,1,* Zhong-Wen Sun,1,* Hui-Jun Lai,2 Jie Yang,1 Ping-Ping Wu,1 Yun-Di Guo,1 Jing Sun1

1Institute of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, China; 2Department of Ultrasound, Suzhou Traditional Chinese Medicine, Suzhou, Jiangsu 215007, China

*These authors contributed equally to this work

Background: (PD-L2), a ligand of programmed cell death protein 1 (PD-1), is an inhibitory receptor of T cells and activated B cells. Many studies have focused on PD-L1, another ligand of PD-1, and the prognostic significance of PD-L1 has been reported in many tumors. However, the expression of PD-L2 in relation to clinical outcomes has not been fully investigated in cancer patients.
Patients and methods: In this study, we investigated the expression of PD-L2 via immunohistochemistry (IHC) in the pathological specimens of 348 patients treated for colorectal cancer (CRC).
Results: Strong PD-L2 expression was found in the cancer tissues from 41% of the CRC patients who also had a high TNM stage and carcinoembryonic antigen (CEA) concentration. We also carried out functional studies in vitro, which showed that PD-L2 did not influence the growth of the CRC cell line HCT116, but increased cell invasion.
Conclusion: Collectively, these findings suggest that PD-L2 may be a potential therapeutic target for CRC.

Keywords: PD-L2, colorectal cancer, migration, therapeutic target

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]